TPST (Tempest Therapeutics) Price-to-Tangible-Book: (As of Sep. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPST Tempest Therapeutics Inc TPST
31 GF Score
Price $1.02
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Price-to-Tangible-Book?

As of today (2026-09-08), Tempest Therapeutics's share price is $1.02. Tempest Therapeutics's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $-0.07. Hence, Tempest Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Tempest Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 6 years, Tempest Therapeutics's highest Price to Tangible Book Ratio was 28.77. The lowest was 0.64. And the median was 2.29.

TPST's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 3.35
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Tempest Therapeutics's share price is $1.02. Tempest Therapeutics's Book Value per Sharefor the quarter that ended in Jun. 2026 was $-0.07. Hence, Tempest Therapeutics's P/B Ratio of today is .

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Tempest Therapeutics Price-to-Tangible-Book Related Terms

Tempest Therapeutics Price-to-Tangible-Book Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Price-to-Tangible-Book Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Price-to-Tangible-Book
Get a 7-Day Free Trial 1.01 0.67 3.62 1.92 2.12

Tempest Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.09 7.19 2.12 28.77 0.00

TPST vs LPCN, CYCN, BCDA: Price-to-Tangible-Book Comparison

For the Biotechnology subindustry, Tempest Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics Price-to-Tangible-Book vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Price-to-Tangible-Book falls into.


TPST
31GF Score
Tempest Therapeutics Inc TPST
Price-to-Tangible-Book is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Price-to-Tangible-Book Calculation

Tempest Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Jun. 2026 )
=1.02/-0.068
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
31GF Score

Get the complete analysis for TPST

Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price